Skip to content
DataLookout
Start free
Menu

NCT07533955

A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 3 → 8 locations
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Recruitment opened
    • Start date changed from estimate of May 2026 to May 19, 2026
    • Site details revised at 3 of 3 sites
    v3
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and Tolerability of Single Ascending Doses of JADE201 in participants with Rheumatoid Arthritis
Timeframe: Day 1 through 36 weeks

Secondary (4)

Cmax
Tmax
AUClast
T1/2

Arms and interventions

JADE201Experimental

Subcutaneous (SC) injection of JADE201

PlaceboExperimental

Subcutaneous (SC) injection of Placebo

Drugs: JADE201, Placebo

Sites

8 sites in 6 countries

Romania 2, Ukraine 2, Bulgaria 1, Georgia 1, Germany 1, Moldova 1